Furazidine (Furamag®) in the management of acute and recurrent cystitis in women
https://doi.org/10.21886/2308-6424-2024-12-6-83-88
Abstract
Cystitis is a common disease worldwide, with up to 36 million cases recorded annually in Russia alone. In 10 % of patients, the condition transforms into a chronic recurrent form. Up to 30 % of visits to outpatient urologists are related to acute or recurrent cystitis. The prevalence of chronic cystitis in women is closely linked to the anatomical and topographical characteristics of the genitourinary system, the presence of gynecological diseases, and hormonal status. Effective treatment for acute or chronic cystitis involves complex therapy, with the key to success lying in the appropriate selection of antibacterial drugs. The current study aimed to analyse the literature data on the effectiveness of Furamag® in the complex treatment of patients with acute and chronic cystitis. To achieve this objective, we conducted a search for articles in scientific databases such as PubMed, Medline, minzdrav.gov.ru, and elibrary.ru using the following keywords: «urinary tract infection», «acute cystitis», «chronic cystitis», «furazidine», «potassium furazidine». Based on the results of our search, we concluded that Furamag® has been successfully used for a long time in the treatment of both acute and chronic cystitis, demonstrating high efficacy and good patient tolerance. This explains its widespread use in routine clinical practice among urologists, gynecologists, and therapists.
Supporting agencies: The study was not sponsored
About the Authors
D. Yu. Pushkar
Russian University of Medicine (RosUniMed); Botkin Moscow Multidisciplinary Scientific and Clinical Centre
Russian Federation
Competing Interests:
Russian Federation
Dmitriy Yu. Pushkar, Dr.Sc.(Med), Full Prof., Acad.
of the RAS
Moscow
Competing Interests:
The authors declare no conflicts of interest
A. N. Bernikov
Russian University of Medicine (RosUniMed); Botkin Moscow Multidisciplinary Scientific and Clinical Centre
Russian Federation
Competing Interests:
Russian Federation
Alexander N. Bernikov, Cand.Sc.(Med), Assoc. Prof. (Docent)
Moscow
Competing Interests:
The authors declare no conflicts of interest
P. I. Rasner
K+31 Medical Centre
Russian Federation
Competing Interests:
Russian Federation
Pavel I. Rasner, Dr.Sc. (Med)
Moscow
Competing Interests:
The authors declare no conflicts of interest
A. V. Bormotin
Russian University of Medicine (RosUniMed); Botkin Moscow Multidisciplinary Scientific and Clinical Centre
Russian Federation
Competing Interests:
Russian Federation
Alexey V. Bormotin, Cand.Sc.(Med), Assoc. Prof. (Docent)
Moscow
Competing Interests:
The authors declare no conflicts of interest
V. V. Dyakov
Russian University of Medicine (RosUniMed); Botkin Moscow Multidisciplinary Scientific and Clinical Centre
Russian Federation
Competing Interests:
Russian Federation
Vladimir V. Dyakov, Cand. Sc. (Med), Assoc. Prof. (Docent)
Moscow
Competing Interests:
The authors declare no conflicts of interest
A. M. Shvedov
Russian University of Medicine (RosUniMed); Botkin Moscow Multidisciplinary Scientific and Clinical Centre
Russian Federation
Competing Interests:
Russian Federation
Andrey M. Shvedov
Moscow
Competing Interests:
The authors declare no conflicts of interest
References
1. Gaitonde S, Malik RD, Zimmern PE. Financial Burden of Recurrent Urinary Tract Infections in Women: A Time-driven Activity-based Cost Analysis. Urology. 2019;128:47-54. DOI: 10.1016/j.urology.2019.01.031
2. Apolihin O.I., Sivkov A.V., Moskaleva N.G., Solntseva T.V., Komarova V.A. Analysis of uronephrological incidence in children in the Russian Federation according to official statistics. Experimental & clinical urology. 2010;(2):4-11. (In Russian). eLIBRARY ID: 17418791; EDN: OREOKZ
3. Jung C, Brubaker L. The etiology and management of recurrent urinary tract infections in postmenopausal women. Climacteric. 2019;22(3):242-249. DOI: 10.1080/13697137.2018.1551871
4. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172. DOI: 10.1177/1756287219832172
5. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653-660. DOI: 10.1038/nrurol.2010.190
6. Malik RD, Wu YR, Christie AL, Alhalabi F, Zimmern PE. Impact of Allergy and Resistance on Antibiotic Selection for Recurrent Urinary Tract Infections in Older Women. Urology. 2018;113:26-33. DOI: 10.1016/j.urology.2017.08.070
7. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009;33(2):111-119. DOI: 10.1016/j.ijantimicag.2008.08.011
8. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1-13. DOI: 10.1016/j.idc.2013.09.003
9. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. EAU Guidelines Office, Arnhem, The Netherlands; 2024. URL: http://uroweb.org/guidelines/compilations-of-all-guidelines/
10. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Edelstein M.V., Perepanova T.S., Kozlov R.S., “DARMIS-2018” Study Group. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(2):134-146. (In Russian). DOI: 10.36488/cmac.2019.2.134-146
11. Ahmed AF, Solyman AA, Kamal SM. Potential host-related risk factors for recurrent urinary tract infection in Saudi women of childbearing age. Int Urogynecol J. 2016;27(8):1245-1253. DOI: 10.1007/s00192-016-2965-0
12. Ali SB, Perdawood D, Abdulrahman R, Al Farraj DA, Alkubaisi NA. Vitamin D deficiency as a risk factor for urinary tract infection in women at reproductive age. Saudi J Biol Sci. 2020;27(11):2942-2947. DOI: 10.1016/j.sjbs.2020.08.008
13. Alsubaie SS, Barry MA. Current status of long-term antibiotic prophylaxis for urinary tract infections in children: An antibiotic stewardship challenge. Kidney Res Clin Pract. 2019;38(4):441-454. DOI: 10.23876/j.krcp.19.091
14. Alghoraibi H, Asidan A, Aljawaied R, Almukhayzim R, Alsaydan A, Alamer E, Baharoon W, Masuadi E, Al Shukairi A, Layqah L, Baharoon S. Recurrent Urinary Tract Infection in Adult Patients, Risk Factors, and Efficacy of Low Dose Prophylactic Antibiotics Therapy. J Epidemiol Glob Health. 2023;13(2):200-211. DOI: 10.1007/s44197-023-00105-4
15. Bakke A. Clean intermittent catheterization--physical and psychological complications. Scand J Urol Nephrol Suppl. 1993;150:1-69. PMID: 8438132
16. Gonzalez Chiappe S, Lasserre A, Chartier Kastler E, Falchi A, Blaizeau F, Blanchon T, Hanslik T, Denys P. Use of clean intermittent self-catheterization in France: A survey of patient and GP perspectives. Neurourol Urodyn. 2016;35(4):528-534. DOI: 10.1002/nau.22752
17. Duffy LM, Cleary J, Ahern S, Kuskowski MA, West M, Wheeler L, Mortimer JA. Clean intermittent catheterization: safe, cost-effective bladder management for male residents of VA nursing homes. J Am Geriatr Soc. 1995;43(8):865-870. DOI: 10.1111/j.1532-5415.1995.tb05528.x
18. Brennand C, von Wilamowitz-Moellendorff A, Dunn S, Wilkinson J, Chadwick T, Ternent L, Oluboyede Y, Wood R, Walton K, Fader M, N’Dow J, Abdel-Fattah M, McClurg D, Little P, Hilton P, Timoney A, Morris N, Thiruchelvam N, Larcombe J, Harrison S, Armstrong H, McColl E, Pickard R. Antibiotic treatment for intermittent bladder catheterisation with once daily prophylaxis (the AnTIC study): Study protocol for a randomised controlled trial. Trials. 2016;17(1):276. DOI: 10.1186/s13063-016-1389-y
19. Perepanova T.S., Sinjakova L.A., Lokshin K.L. Cistit u zhenshhin : Klinicheskie rekomendacii. M.: Rossijskoe obshhestvo urologov; 2021. (In Russian). URL: https://legalacts.ru/doc/klinicheskie-rekomendatsii-tsistit-u-zhenshchin-utv-minzdravom-rossii/
20. Piédrola Angulo G. La adherencia bacteriana en la patogenia de las ITU [Bacterial adherence in pathogenesis of urinary tract infectious]. An R Acad Nac Med (Madr). 2003;120(3):409-419; discussion 419-425. (In Spanish). PMID: 15027698
21. Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol. 2018;219(1):40-51. DOI: 10.1016/j.ajog.2017.12.231
22. Lugtenberg M, Burgers JS, Zegers-van Schaick JM, Westert GP. Guidelines on uncomplicated urinary tract infections are difficult to follow: perceived barriers and suggested interventions. BMC Fam Pract. 2010;11:51. DOI: 10.1186/1471-2296-11-51
23. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 91: Treatment of urinary tract infections in nonpregnant women. Obstet Gynecol. 2008;111(3):785-794. DOI: 10.1097/AOG.0b013e318169f6ef
24. Kashanian J, Hakimian P, Blute M Jr, Wong J, Khanna H, Wise G, Shabsigh R. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int. 2008;102(11):1634-1637. DOI: 10.1111/j.1464-410X.2008.07809.x
25. Yakovlev S.V., Logvinov L.A., Klochkov I.A., Polikarpova S.V., Panin A.G., Kovyrshina L.A., Boitsov A.G., Bova S.I., Rychova S.B. Sheremet O.M. Klinicheskaya i bakteriologicheskaya ehffektivnost’ preparata «FuramaG» u patsientov s ostrym tsistitom. Infektsii i antimikrobnaya terapiya. 2005;7(4):120-126. (In Russian).
26. Bielec F, Brauncajs M, Pastuszak-Lewandoska D. Nitrofuran Derivatives Cross-Resistance Evidence-Uropathogenic Escherichia coli Nitrofurantoin and Furazidin In Vitro Susceptibility Testing. J Clin Med. 2023;12(16):5166. DOI: 10.3390/jcm12165166
27. Klesiewicz K., Karczewska E., Nowak P., Mrowiec P., Skiba-Kurek I., Bia£ecka J., Majka Z., Berdzik-Kalarus S., Budak A., Zajdel P. Comparative in vitro studies of furazidin and nitrofurantoin activities against common uropathogens including multidrug-resistant strains of E.coli and S.aureus. Acta poloniae pharmaceutica. 2018;75(3):803-812.
28. Männistö P, Karttunen P. Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. Int J Clin Pharmacol Biopharm. 1979;17(6):264-270. PMID: 468451
29. Slapsyte G, Jankauskiene A, Mierauskiene J, Lazutka JR. Cytogenetic analysis of children under long-term antibacterial therapy with nitroheterocyclic compound furagin. Mutat Res. 2001;491(1-2):25-30. DOI: 10.1016/s1383-5718(01)00131-0
30. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy. Clin Nephrol. 2000;53(4):257-263. PMID: 10809412
31. Perepanova T.S., Khazan P.L. Primenenie nitrofuranov pri infektsii mochevykh putei. Ehffektivnaya farmakoterapiya. 2007;(20):20-30. (In Russian). eLIBRARY ID: 35205094; EDN: XSIEIP
32. Panin A.G., Boitsov A.G., Kovyrshina L.A., Topuzov M.E., Pryalukhin A.E. Furamag use in acute cystitis treatment. Vestnik Sankt-Peterburgskoi Gosudarstvennoi Meditsinskoi Akademii im. I.I. Mechnikova. 2006;7(3):174-176. (In Russian). eLIBRARY ID: 16336555. EDN: NTMVAJ
33. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. Current trends in the treatment of chronic recurrent bacterial cystitis. Urologiia. 2020;(6):52-57. (In Russian). DOI: 10.18565/urology.2020.6.52-57
34. Kurnosova N.V., Kuzmenko A.V., Kuzmenko V.V. Morphometric estimation of the chronic bacterial cystitis treatment by Furamag. “Postgraduate Doctor” journal. 2011;44(1.4):578-583. (In Russian). eLIBRARY ID: 16537033; EDN: NXWWRH
35. Davydov A.V., Neymark A.I. Evaluation of the effectiveness of the herbal remedies Canephron N application in the complex treatment of patients with chronic cystitis. Effektivnaya farmakoterapiya. 2019;15(10): 20-23. (In Russian). DOI: 10.33978/2307-3586-2019-15-10-20-23
36. Perepanova T.S., Khazan P.L., Volkova E.M., Egamberdiev D.K., Tolordava E.R., Romanova Yu.M. Problemy lecheniya retsidiviruyushchei infektsii nizhnikh mochevykh putei. Effektivnaya farmakoterapiya. 2011;(43):38-43. (In Russian). eLIBRARY ID: 21705883; EDN: QLMTQW
Review
For citations:
Pushkar D.Yu., Bernikov A.N., Rasner P.I., Bormotin A.V., Dyakov V.V., Shvedov A.M. Furazidine (Furamag®) in the management of acute and recurrent cystitis in women. Urology Herald. 2024;12(6):83-88. (In Russ.) https://doi.org/10.21886/2308-6424-2024-12-6-83-88
Views:
1175
Email this article 
